Novartis: Amgen migraine drug reduces symptoms.
(CercleFinance.com) - A phase II study has showed that Amgen's erenumab reduced monthly migraine days in patients with chronic migraine for whom previous preventive treatments have failed, Novartis said late on Thursday.
"These data highlight that erenumab has the potential to be a life-changing option for migraine patients with the highest unmet need - those who have tried and failed previous preventive treatments," commented Professor Messoud Ashina at the University of Copenhagen.
Studies have shown that up to 80% of people with migraine discontinue preventive treatment within one year.
Since 2015, Amgen and Novartis have collaborated to jointly develop and market treatments in the field of migraine, including Amgen's erenumab, for which Novartis has exclusive rights in Europe.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"These data highlight that erenumab has the potential to be a life-changing option for migraine patients with the highest unmet need - those who have tried and failed previous preventive treatments," commented Professor Messoud Ashina at the University of Copenhagen.
Studies have shown that up to 80% of people with migraine discontinue preventive treatment within one year.
Since 2015, Amgen and Novartis have collaborated to jointly develop and market treatments in the field of migraine, including Amgen's erenumab, for which Novartis has exclusive rights in Europe.
Copyright (c) 2017 CercleFinance.com. All rights reserved.